AMEX · MAIA
MAIA Biotechnology, Inc.
$1.18+$0.02 (+1.72%)
MAIA Biotechnology, Inc.’s quoted price sits in the lower half of its reported 52-week range, 63.01% below the high.
Loading market information…
NASDAQ · ATHE · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Alterity Therapeutics Limited’s quoted price sits in the lower half of its reported 52-week range, 62.08% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Alterity Therapeutics Limited’s next earnings report is currently expected on Mar 4, 2027, with estimated earnings per share of -$0.03. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Alterity Therapeutics Limited’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Alterity Therapeutics Limited, an Australian biopharmaceutical firm, focuses on the discovery and development of novel drug treatments for various neurological disorders, such as Alzheimer's, Huntington's, and Parkinson's diseases. Its prominent experimental therapy, ATH434, has completed Phase I clinical trials targeting Parkinson's disease. The company is also advancing PBT2, a compound that has successfully undergone Phase IIa clinical testing for Alzheimer's disease. Established in 1997, the entity was formerly known as Prana Biotechnology Limited before rebranding to Alterity Therapeutics Limited in April 2019, and its main operations are based in Melbourne, Australia.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:32 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Aug 29, 2024 |
| -$0.80-1,067.36% vs estimate |
| $1.41M+55.2% vs estimate |
| Q2 2024 | Apr 11, 2024 | -$0.00 | $1.06M |
|---|
| Q2 2024 | Feb 28, 2024 | -$1.10-702.77% vs estimate | $77.10K-91.95% vs estimate |
|---|
THE ANALYST VIEW
8 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 3 contributors · Median target $10.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$1.18+$0.02 (+1.72%)
MAIA Biotechnology, Inc.’s quoted price sits in the lower half of its reported 52-week range, 63.01% below the high.
$1.02$0.00 (0.0%)
Annovis Bio, Inc.’s quoted price sits in the lower half of its reported 52-week range, 81.45% below the high.
$1.43-$0.02 (-1.38%)
NanoViricides, Inc.’s quoted price sits in the lower half of its reported 52-week range, 35.87% below the high.
$5.34$0.00 (0.0%)
Generation Bio Co.’s quoted price sits in the upper half of its reported 52-week range, 28.95% below the high.
$2.04$0.00 (0.0%)
Mural Oncology plc’s quoted price sits in the lower half of its reported 52-week range, 56.96% below the high.
$0.20-$0.04 (-16.55%)
IGC Pharma, Inc.’s quoted price sits in the lower half of its reported 52-week range, 55.81% below the high.
$3.08-$0.03 (-0.96%)
Evaxion Biotech A/S’s quoted price sits in the lower half of its reported 52-week range, 55.49% below the high.
$0.36-$0.03 (-8.4%)
Dyadic International, Inc.’s quoted price sits in the lower half of its reported 52-week range, 77.44% below the high.
